COLORECTAL CANCER

PD1 blockade for advanced MSI-H CRC

In a phase III, open-label trial, 307 treatment-naive patients with metastatic microsatellite-instability-high (MSI-H)–mismatch-repair-deficient colorectal cancer were randomly assigned to either pembrolizumab or 5-fluorouracil-based therapy with or without bevacizumab or cetuximab as first-line treatment. At a median follow-up 32.4 months, patients in the pembrolizumab group had higher progression-free survival than patients in the chemotherapy group (median 16.5 versus 8.2 months; HR 0.60; 95% CI 0.45–0.80; P = 0.0002). 43.8% of the pembrolizumab group and 33.1% of the chemotherapy group had an overall response. Serious treatment-related adverse effects were lower in the pembrolizumab group.

References

Original article

  1. André, T. et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020)

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jordan Hindson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hindson, J. PD1 blockade for advanced MSI-H CRC. Nat Rev Gastroenterol Hepatol 18, 82 (2021). https://doi.org/10.1038/s41575-021-00415-7

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing